Real world characteristics and burden of patients initiating advanced systemic therapy in the TARGET-DERM atopic dermatitis registry.

Challenge

Before prescribing advanced systemic therapies in AD, clinicians and sponsors needed real-world data on the characteristics, disease burden, and comorbidity profile of patients who newly initiate these agents in clinical practice—data that registration trials cannot provide due to their strict eligibility criteria.

Solution

A retrospective observational cohort study using TARGET-DERM AD characterized patients initiating advanced systemic therapy (AST) for the first time, describing demographics, disease severity, comorbidities, prior treatment history, and concomitant therapy use at and after AST initiation.

Impact

Characterizing the real-world AST initiator population—including their high comorbidity burden and persistent concomitant therapy use at 12 months—establishes the baseline context for post-authorization effectiveness studies and informs label communication for Amgen/Kyowa Kirin's AD pipeline assets.